Cite
HARVARD Citation
Bouvier, A. et al. (2021). Molecular classification and prognosis in younger adults with acute myeloid leukemia and intermediate‐risk cytogenetics treated or not by gemtuzumab ozogamycin: Final results of the GOELAMS/FILO acute myeloid leukemia 2006‐intermediate‐risk trial. European journal of haematology. pp. 111-121. [Online].